A Phase I, Single-centre, Randomised, Open-label, Cross-over Study to Evaluate the Pharmacokinetics of a Single Dose of two Formulations of Orally Administered Tetrahydrocannabinol/Cannabidiol Combination in Fed Healthy Volunteers.
100 Clinical Results associated with AusCann Group Holdings Ltd.
0 Patents (Medical) associated with AusCann Group Holdings Ltd.
100 Deals associated with AusCann Group Holdings Ltd.
100 Translational Medicine associated with AusCann Group Holdings Ltd.